Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients

Journal of Psychiatric Research

Volumn 48, Issue 1, 2014, Pages 94-101

  Gassó, Patricia ^a,d   Mas, Sergi ^a,d,e   Molina, Oriol ^b   Lafuente, Amalia ^a,d,e   Bernardo, Miquel ^a,c,d,e   Parellada, Eduard ^a,c,d,e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotic na ve; Apoptosis; Fibroblast culture; First episode; Schizophrenia; Skin biopsy

Indexed keywords

CASPASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLSERINE; PROTEIN AKT1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; STAUROSPORINE; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CELL GROWTH; CELL VIABILITY; CHROMATIN CONDENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBROBLAST CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIPID TRANSPORT; MALE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; SCHIZOPHRENIA; SKIN FIBROBLAST;

ANTIPSYCHOTIC-NAÏVE; APOPTOSIS; FIBROBLAST CULTURE; FIRST-EPISODE; SCHIZOPHRENIA; SKIN BIOPSY;

ADULT; APOPTOSIS; CASPASE 3; CELL SURVIVAL; CELLS, CULTURED; CHROMATIN; FEMALE; FIBROBLASTS; HUMANS; MALE; PHOSPHATIDYLSERINES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84888429628     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.09.017     Document Type: Article

References (52)

1. Auburger G., Klinkenberg M., Drost J., Marcus K., Morales-Gordo B., Kunz W.S., et al. Primary skin fibroblasts as a model of Parkinson's disease. Molecular Neurobiology 2012, 46:20-27.
2. Bai O., Zhang H., Li X.M. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Research 2004, 1010:81-86.
3. Benedetti F., Poletti S., Radaelli D., Bernasconi A., Cavallaro R., Falini A., et al. Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-β activity. Genes, Brain and Behaviour 2010, 9:365-371.
4. Benes F.M., Walsh J., Bhattacharyya S., Sheth A., Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Archives of General Psychiatry 2003, 60:359-364.
5. Benes F.M., Matzilevich D., Burke R.E., Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Molecular Psychiatry 2006, 11:241-251.
6. Beurel E., Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Progress in Neurobiology 2006, 79:173-189.
7. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
8. Cahn W., Hulshoff Pol H.E., Lems E.B., van Haren N.E., Schnack H.G., van der Linden J.A., et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Archives of General Psychiatry 2002, 59:1002-1010.
9. Cardinale A., Nastrucci C., Cesario A., Russo P. Nicotine: specific role in angiogenesis, proliferation and apoptosis. Critical Reviews in Toxicology 2012, 42:68-89.
10. Cascella N.G., Takaki M., Lin S., Sawa A. Neurodevelopmental involvement in schizophrenia: the olfactory epithelium as an alternative model for research. Journal of Neurochemistry 2007, 102:587-594.
11. Catts V.S., Catts S.V., McGrath J.J., Féron F., McLean D., Coulson E.J., et al. Apoptosis and schizophrenia: a pilot study based on dermal fibroblast cell lines. Schizophrenia Research 2006, 84:20-28.
12. Catts V.S., Catts S.V., O'Toole B.I., Frost A.D. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatrica Scandinavica 2008, 117:323-336.
13. Chen X., Sun C., Chen Q., O'Neill F.A., Walsh D., Fanous A.H., et al. Apoptotic engulfment pathway and schizophrenia. PLoS One 2009, 4:e6875.
14. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
15. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia Bulletin 2009, 35:528-548.
16. Féron F., Perry C., Hirning M.H., McGrath J., Mackay-Sim A. Altered adhesion, proliferation and death in neural cultures from adults with schizophrenia. Schizophrenia Research 1999, 40:211-218.
17. Gassó P., Mas S., Molina O., Bernardo M., Lafuente A., Parellada E. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Progress in Neuropsychopharmacology and Biological Psychiatry 2012, 36:71-77.
18. Gilman C.P., Mattson M.P. Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility?. Neuromolecular Medicine 2002, 2:197-214.
19. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research 2006, 81:47-63.
20. Gottfried Y., Rotem A., Klein E., Larisch S. The pro-apoptotic ARTS/Sept4 protein is significantly reduced in post-mortem brains from schizophrenic patients. Schizophrenia Research 2007, 96:257-266.
21. Grinshpoon A., Barchana M., Ponizovsky A., Lipshitz I., Nahon D., Tal O., et al. Cancer in schizophrenia: is the risk higher or lower?. Schizophrenia Research 2005, 73:333-341.
22. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16621-16626.
23. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
24. Jarskog L.F., Gilmore J.H., Selinger E.S., Lieberman J.A. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biological Psychiatry 2000, 48:641-650.
25. Jarskog L.F., Selinger E.S., Lieberman J.A., Gilmore J.H. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. American Journal of Psychiatry 2004, 161:109-115.
26. Jarskog L.F., Glantz L.A., Gilmore J.H., Lieberman J.A. Apoptotic mechanisms in the pathophysiology of schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2005, 29:846-858.
27. Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Lee C.U., Ciszewski A.A., et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. American Journal of Psychiatry 2003, 160:156-164.
28. Kim H.W., Rapoport S.I., Rao J.S. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiology of Disease 2010, 37:596-603.
29. Kim N.R., Park S.W., Lee J.G., Kim Y.H. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells. Progressive Neuropsychopharmacology and Biological Psychiatry 2008, 32:633-642.
30. Kirkpatrick B. Schizophrenia as a systemic disease. Schizophrenia Bulletin 2009, 35:381-382.
31. Kozlovsky N., Belmaker R.H., Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. American Journal of Psychiatry 2000, 157:831-833.
32. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry 2001, 50:884-897.
33. Lieberman J.A., Bymaster F.P., Meltzer H.Y., Deutch A.Y., Duncan G.E., Marx C.E., et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacological Reviews 2008, 60:358-403.
34. Mahadik S.P., Mukherjee S. Cultured skin fibroblasts as a cell model for investigating schizophrenia. Journal of Psychiatric Research 1996, 30:421-439.
35. Matigian N., Windus L., Smith H., Filippich C., Pantelis C., McGrath J., et al. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Molecular Psychiatry 2007, 12:815-825.
36. Mattson M.P., Keller J.N., Begley J.G. Evidence for synaptic apoptosis. Experimental Neurology 1998, 153:35-48.
37. McCurdy R.D., Féron F., Perry C., Chant D.C., McLean D., Matigian N., et al. Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses. Schizophrenia Research 2006, 82:163-173.
38. Porter A.G., Jänicke R.U. Emerging roles of caspase-3 in apoptosis. Cell Death and Differentiation 1999, 6:99-104.
39. Qing H., Xu H., Wei Z., Gibson K., Li X.M. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. European Journal of Neuroscience 2003, 17:1563-1570.
40. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2010, 215:598-605.
41. Rieske P., Krynska B., Azizi S.A. Human fibroblast-derived cell lines have characteristics of embryonic stem cells and cells of neuro-ectodermal origin. Differentiation 2005, 73:474-483.
42. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler J.F., et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nature Medicine 1999, 5:1194-1198.
43. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biological Psychiatry 1999, 45:17-25.
44. Ukai W., Ozawa H., Tateno M., Hashimoto E., Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. Journal of Neural Transmission 2004, 111:667-681.
45. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002, 3. RESEARCH0034.
46. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Südhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041.
47. Wang L., Lockstone H.E., Guest P.C., Levin Y., Palotás A., Pietsch S., et al. Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. Journal of Proteome Research 2010, 9:521-527.
48. Wei Z., Mousseau D.D., Richardson J.S., Dyck L.E., Li X.M. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. Journal of Neuroscience Research 2003, 74:942-947.
49. Wiesel F.A., Edman G., Flyckt L., Eriksson A., Nyman H., Venizelos N., et al. Kinetics of tyrosine transport and cognitive functioning in schizophrenia. Schizophrenia Research 2005, 74:81-89.
50. Yang Y., Xiao Z., Chen W., Sang H., Guan Y., Peng Y., et al. Tumor suppressor gene TP53 is genetically associated with schizophrenia in the Chinese population. Neuroscience Letters 2004, 369:126-131.
51. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008, 9:47-59.
52. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.